Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data

INTRODUCTION: Conventional pharmaceutical interventions for inflammatory bowel disease (IBD) provide limited disease/symptom control and are associated with an increased risk of adverse events (AEs). These limitations increase patient morbidity, medical resource utilization (MRU), and costs. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Gráinne H., Tatro, Amanda R., Oh, Young S., Reddy, Sheila R., Ananthakrishnan, Ashwin N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822802/
https://www.ncbi.nlm.nih.gov/pubmed/31562607
http://dx.doi.org/10.1007/s12325-019-01095-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822802/
https://www.ncbi.nlm.nih.gov/pubmed/31562607
http://dx.doi.org/10.1007/s12325-019-01095-1

Ejemplares similares